Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE: Long-acting octreotide for type 1 gastric neuroendocrine tumors
ChiCTR2100053329Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of octreotide in gastric neuroendocrine neoplasm and apudoma (NET) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective Response Rate, Serum chromogranin A (CgA) and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
octreotide
03
Conditions
gastric neuroendocrine neoplasmapudoma (NET)
Beyond the preview
Go deeper on ChiCTR2100053329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053329.